Benefits Investigation (BI)

LUCENTIS^® Access Solutions can help your practice facilitate a benefits investigation (BI) on behalf of your LUCENTIS^® (ranibizumab injection) patient before treatment starts. This way, you can better understand your patient's health plan coverage for some or all of the costs associated with LUCENTIS treatment. The BI can also determine if patient assistance might be needed.

To have LUCENTIS Access Solutions conduct a BI, all you need to do is request our assistance on the signed Statement of Medical Necessity (SMN) form.

By conducting a BI, you know what is covered before your practice begins treatment. Also, some health plans require a prior authorization (PA) for the use of LUCENTIS. The BI helps determine if a PA is needed.

Note: This description of a BI is for informational purposes only. The completion and submission of a BI are the responsibility of the patient and your office. LUCENTIS Access Solutions makes no representation or guarantee concerning reimbursement or coverage for any service or item.

To learn more about the benefits investigations process, click here.

Who is LUCENTIS for?

LUCENTIS^® (ranibizumab injection) is a prescription medicine for the treatment of patients with Wet Age-Related Macular Degeneration (AMD) and Macular Edema Following Retinal Vein Occlusion (RVO).

What important safety information should I know about LUCENTIS?

LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious eye infections. LUCENTIS should not be used in patients who have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients. LUCENTIS patients have had increases in eye pressure within 1 hour of an injection. Serious side effects also include inflammation inside the eye, and rarely, problems related to the injection procedure, such as cataracts. Although not common, some LUCENTIS patients have had strokes or heart attacks. If your eye becomes red, sensitive to light, painful, or has a change in vision, you should call or visit your eye doctor right away. Ask your doctor if you have questions or want more information.

For additional safety information, please talk to your doctor and see the LUCENTIS full prescribing information.

LUCENTIS^® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.